Skip to main content
. 2016 Feb 18;6:21228. doi: 10.1038/srep21228

Figure 2. Inhibition of miR-182 prevents NO-induced cardiomyocyte hypertrophy.

Figure 2

(a) miR-182 is upregulated in NRCs treated for 24 hrs with NO donor (DETA-NONOate, 100 μM), but not in PlGF (50 ng/ml) or Ang II (0.5 μM) treated NRCs. (b) miR-182 inhibition with anti-miR-182 (50 nM) in NO-treated NRCs, compared with miR-scramble (50 nM). (c) Anti-miR-182 prevents the increase in cell size in NO-treated NRCs. (d) Representative NRCs transfected with anti-miR-182, miR-182 mimic and miR-scramble with and without NO donor treatment for 24 hrs compared with control NRCs (co-staining with an anti-α-actinin sarcomeric Ab and DAPI). (e) Western blot analysis of AktSer473 and p70-S6KThr389. (f) Relative change in Akt activation at AktSer47. (g) Relative change in p70S6K activation at p70-S6KThr389. (h) miR-182 mimic promotes NRC hypertrophy. (i) Representative HUVECs sprouting (calcein AM staining) after transfection with miR-182 mimic or miR-scramble (50 nM). (j) Quantitative analysis of the tube area. * P <  0.05; **P < 0.01; ***P < 0.001.